Agus, D. B., Akita , R. W., Fox, W. D., Le wi s, G. D., Hi ggi ns, B., Pi sacane, P. I.,
Lofgren, J. A., Tindell , C., Eva ns, D. P., Maie se , K., Sche r, H. I., & Sli wkowski ,
M. X. (2002). Ta rgeti ng liga nd - activate d ErbB2 signaling inhibi ts brea st a nd
prostat e t umor growt h. C ance r c el l, 2 (2), 127–137.
Att wood, M. M., Jonsson, J., Rask -Ande rsen, M., & Schi öth, H. B. (2020). Soluble
ligands a s drug targets. Nat ure rev iews. Drug di scove ry, 19 (10), 695 –710.
Baba , K., Oshita , A., Kohyama, M., Inoue, S., Kuroo, Y., Yamaguchi , T., N akam ura ,
H., Sugiyama , Y., Taza ki, T., Sa sa ki, M., Imam ura , Y., Daim aru, Y., Ohdan, H., &
Naka mit su, A. (2015). Succe ssful trea tment of conve rsi on che mothe rapy for
initiall y unresec table sync hronous c olorectal live r me tastasis. World j ournal of
gastroent erology, 21 (6), 1982 –1988.
Baeue rle, P. A., & Gire s, O. (2007). E pCAM (CD326) finding i ts role in ca ncer.
Briti sh j ournal of cancer, 96(3), 417 –423.
Blasco- Benito, S., More no, E ., Seij o -Vila , M., Tundi dor, I., Andrada s, C., Caffare l,
M. M., Ca ro -Villal obos, M., Urigüen, L., Diez - Alarci a, R., Moreno -Bueno, G.,
Hernández, L ., Ma nso, L ., Homar - Ruano, P., Mc Cormick, P. J., Bibic , L., Bernadó Morale s, C., Arriba s, J., Ca nal s , M., Ca sadó, V., Canela , E. I., … Sánc hez, C.
(2019). The rape utic ta rgeti ng of HER2 - CB2R heteromers in HE R2 -posit ive brea st
cancer. Proceedings of t he Nati onal Academy of Scie nce s of the United State s of
Ame rica, 116 (9), 3863 –3872.
Borl ak, J., Lä nger, F. , Spanel , R., Schöndorfer, G., & Di ttric h, C. (2016). Immune mediate d li ver inj ury of t he ca nc er therapeutic anti body catuma xomab ta rgeti ng
65
EpCAM, CD3 and Fc γ rece ptors. Onc otarge t, 7(19), 28059–28074.
Campbell, M. R., Ruiz - Sae nz, A., Pete rson, E., Agnew, C., Ayaz , P., Garfinkle, S.,
Littlefiel d, P., Steri, V., Oeffi nger, J., Sampa ng, M., Sha n, Y., Sha w, D. E ., Jura ,
N., & Moa sser, M. M. (2022). Targeta ble HE R3 funct ions driving tum ori geni c
signali ng in HE R2 -amplifie d ca nc ers. Cell re port s, 38 (5), 110291.
Campbell, M. R., Ruiz - Sae nz, A., Zhang, Y., Pe terson, E ., Ste ri, V., Oeffinger, J.,
Sampang, M., Jura , N., & Moasse r, M. M. (2022). E xtensi ve conformationa l a nd
physica l pla sticit y protect s HE R2 -HER3 t um ori genic signaling. Ce ll report s, 38 (5),
110285.
Casa letto, J. B., Geddie, M. L ., Abu - Yousif, A. O., Ma sson, K., Ful gham , A.,
Boudot , A., Mai wald, T., Kea rns, J. D., Kohli , N., Su, S., Ra zlog, M., Raue, A.,
Kalra , A., Håka nsson, M., Logan, D. T., Welin, M., Chattopadhya y, S., Ha rms, B.
D., Niel sen, U. B., S choebe rl, B., … MacBeat h, G. (2019). MM - 131, a bi spec ific
anti- Met/E pCAM
m Ab,
i nhi bit s
HGF - depe nde nt
and
HGF-i nde pendent
Met
signali ng t hrough c onc urre nt binding to E pCAM. P roceedi ngs of the National
Acade my of Scie nce s of t he United States of A me rica, 116 (15), 7533–7542.
Choe , W., Durga nna var, T. A., & Chung, S. J. (2016). Fc - Binding Liga nds of
Immunoglobuli n G: An Overvie w of Hi gh Affini ty Proteins and Pepti des. Mate ri al s
(Basel, Swit ze rland), 9 (12), 994.
Conradi , L. C., Spitz ner, M., Metz ger, A. L ., Kisl y, M., Mi ddel , P., Bohne nbe rger,
H., Gae dcke, J., Ghadimi , M. B., Liersch, T., Rüsc hoff, J., Bei ßba rt h, T., König,
A., & Gra de, M. (2019). Com bined targeting of HER -2 and HER- 3 re pre sents a
prom isi ng the rapeutic strate gy in colorectal cancer. B MC cancer, 19 (1), 880.
Console, L., Sc ali se, M., Sale rno, S., Sca nga , R., Gi udi ce, D., De Ba rtol o, L.,
66
Tonazzi , A., & Indi veri , C. (2022). N - glyc osylati on i s c rucial for traffic king and
stability of SL C3A2 (CD98). Scie ntific re port s, 12(1), 14570.
Cui, J., Xia , T., Xie, D., Gao, Y., Jia, Z., Wei, D., Wa ng, L., Huang, S., Quan, M.,
& Xie , K. (2016). HGF/ Met a nd FOXM1 form a positi ve feedback loop a nd re nde r
pancreatic c ance r cell s re si stanc e to Met inhibi tion and a ggre ssive phe not ype s.
Onc oge ne, 35(36), 4708 –4718.
De Boec k, A., Pa uwe ls, P., He nse n, K., Rumme ns, J. L., We stbroe k, W., He ndrix,
A., Maynard, D., De nys, H., L ambein, K., Braem s, G., Gespac h, C., Brac ke, M., &
De Wever, O. (2013). Bone ma rrow - deri ved mesenc hymal stem c ells promot e
colorectal canc er progre ssion t hrough parac rine neure gul in 1/ HE R3 signalli ng. Gut,
62(4), 550 –560.
De Wever, O., Nguyen, Q. D., Van Hoorde, L., Bracke , M., Bruyne el, E., Gespac h,
C., & Ma reel , M. (2004). Te na sci n -C and SF/ HGF produc ed by m yofibrobla st s i n
vitro provi de convergent pro -inva sive si gnal s to huma n col on canc er cells through
RhoA and Rac. FASEB journal : of ficial publicati on of t he Fe derati on of A me ric an
Societi es for Expe ri me ntal Biol ogy, 18 (9), 1016– 1018.
Dey, N., William s, C., Le yland - Jones, B., & De, P. (2015). A critical role for HE R3
in HER2-am plifi ed a nd non -am pli fied brea st c ance rs: functi on of a kina se -dea d
RT K. Ameri can journal of t ranslat ional research, 7 (4), 733 –750.
Di Renz o, M. F., Oli vero, M., Gi a comin i , A., Port e, H., Cha st re, E., Mirossa y, L.,
Nordli nger, B., Bretti, S., Bottardi , S., & Gi ordano, S. (1995). Ove re xpre ssi on and
amplifi cation of t he met/ HGF re c eptor gene duri ng t he progre ssi on of c olorectal
cancer. Cli nical cance r re search : an offici al j ournal of t he A me rican A ssociation
for Cance r Re search, 1 (2), 147 –154.
67
Di wanji , D., Trenker, R., T haker, T. M., Wang, F., Aga rd, D. A., Ve rba, K. A., &
Jura, N. (2021). St ruc tures of the HER2 - HE R3- NRG1β com plex reveal a dynamic
dimer inte rfac e. Nat ure, 60 0(7888), 339–343.
Dua , R., Zha ng, J., Nhontha chit , P., Penuel, E., Pe tropoulos, C., & Pa rry, G. (2010).
EGFR ove r-e xpressi on and acti vati on i n high HER2, E R negati ve brea st ca ncer cell
line induce s t ra stuz uma b re si stanc e. Bre ast cance r re se arc h and t re at m ent , 122 (3),
685 –697.
Engelma n, J. A., Zej nul lahu, K., Mit sudomi , T., Song, Y., Hyland, C., Park, J. O.,
Lindema n, N., Gale, C. M., Z hao, X., Chri stense n, J., Kosaka , T., Holm es, A. J.,
Roge rs, A. M., Cappuzz o, F., Mok, T., Lee , C., Johnson, B. E ., Ca nt le y, L. C., &
Jänne, P. A. (2007). MET ampli fic ation leads to ge fiti nib re si stance i n lung cancer
by a ctivat ing ERBB3 si gnali ng. Sc ience (Ne w York, N.Y.), 316 (5827), 1039 –1043.
Farshba f, M., Khosrousha hi, A. Y., Moja rad -Ja bali , S., Za rebkohan, A., Valizadeh ,
H., & Walker, P. R. (2020). Cell surface GRP78: An em ergi ng imaging marker and
thera peutic target for cancer. J ournal of c ont rolle d release : offici al journal of the
Cont rolled Rele ase Societ y, 328 , 932– 941.
Fera l, C. C., Ni shi ya, N., Fencz ik, C. A., Stuhlmann, H., Slepak, M., & Gi nsberg,
M. H. (2005). CD98hc (SL C3A2) mediate s inte gri n si gnal ing. Proce edings of t he
Nati onal Ac ade my of Scie nce s of t he Unit ed States of A me rica, 102 (2), 355 –360.
Fot iadi s, D., Ka nai , Y., & Pa lací n, M. (2013). The SL C3 and SLC7 fami lie s of
amino acid tra nsporte rs. Mole cul ar aspect s of me dici ne, 34 (2 -3), 139–158.
Fu, J., Su, X., Li , Z ., De ng, L ., Li u, X., Fe ng, X., & Pe ng, J. (2021). HGF/c - MET
pathway in cancer: from molec ular characte rizati on to cli nical e videnc e. Onc oge ne,
40(28), 4625 –4651.
68
Fu, W., Lei , C., Yu, Y., Liu, S., Li , T., Lin, F., Fa n, X., Shen, Y., Di ng, M., Tang,
Y., Ye , X., Ya ng, Y., & Hu, S. (2019). E GFR/ Notc h Anta gonist s Enhance t he
Response to Inhibit ors of the PI3K - Akt Pa thway by Dec reasing Tumor- Initi ating
Cell Frequenc y. Cli nical c ance r research : an official journal of the A me rican
Associ ation for Cance r Re se arc h, 25 (9), 2835–2847.
Gandull o- Sá nchez , L., Ocaña , A., & Pa ndiel la, A. (2022). HE R3 i n cancer: from
the bench to t he be dside . Journal of ex perime ntal & c linic al cance r researc h : CR ,
41(1), 310.
Gedye, C. A., Hussai n, A., Paterson, J., Smrke, A., Sai ni, H., Si rskyj , D., Perei ra,
K., Lobo, N., Ste wart , J., Go, C., Ho, J., Medrano, M., Hyatt, E ., Yua n, J., Lauriault ,
S., Meyer, M., Kondratye v, M., va n de n Be ucke n, T., Jewett, M., Dirks, P., … Aille s,
L. E. (2014). Cell surface profil ing using hi gh -throughput flow cytomet ry: a
platform for bioma rke r di scovery and ana lysi s of cel lula r hete rogene ity. Pl oS one,
9(8), e105602.
Gij sen, M., King, P., Perera , T., Parker, P. J., Harri s, A. L ., La rijani , B., & Kong,
A. (2010). HER2 phosphorylati on is mai ntaine d by a PKB negati ve feedbac k loop
in re sponse to a nti - HE R2 herce ptin in brea st ca ncer. P LoS biol ogy, 8(12), e 1000563.
Gire s, O., Pan, M., Schi nke , H., Canis, M., & Bae uerle, P. A. (2020). E xpressi on
and function of e pithel ial cell adhesion m olecule EpCAM: where are we a fter 40
years?. Cance r me tastasi s revi ews, 39 (3), 969– 987.
Gui x, M., Fa ber, A. C., Wa ng, S. E., Oliva re s, M. G., Song, Y., Qu, S., Rine hart ,
C., Sei del, B., Yee , D., Artea ga, C. L., & Engelman, J. A. ( 2008). Ac qui red
resi sta nce to EGFR t yrosine ki nase inhibit ors in cance r ce lls i s me diated by loss
of IGF- binding protei ns. The Journal of cl inic al inve sti gat ion, 118 (7), 2609–2619.
69
Gygi, S. P., Roc hon, Y., Franza , B. R., & Ae bersol d, R. (1999). Correl ation bet ween
prot ein and mRNA a bundance i n yea st. Molecul ar and cell ular biology, 19 (3),
1720– 1730.
Gökbuget , N., Dom bre t, H., Bonifacio, M., Reichle, A., Graux, C., Fa ul, C.,
Diedric h, H., Topp, M. S., Brüggema nn, M., Horst , H. A., Ha velange, V.,
Stie glmaier, J., We ssel s, H., Ha ddad, V., Benj amin, J. E., Z ugmai er, G., Na gorse n,
D., & Bargou, R. C. (2018). Bl ina tumoma b for mi nimal re sidual di sease in a dults
with B -cell precursor acut e l ymphobla stic leukemia . Bl ood, 131(14), 1522 –1531.
Hana han , D. (2022). Hal lm arks of Ca ncer: Ne w Dime nsions. Canc er di scove ry,
12(1), 31– 46.
Hara , Y., Minam i, Y., Yoshimot o, S., Haya shi, N., Yama saki, A., Ueda , S., Ma suko,
K., & Ma suko, T. (2020). Anti -tumor e ffect s of an anta goni stic m Ab agai nst t he
ASCT 2 amino acid t ransporter on KRAS -m utate d hum an colore ctal cancer cell s.
Canc er medici ne, 9 (1), 302– 312.
Harbeck, N., Bec kmann, M. W., Rody, A., Schnee wei ss, A., Müller, V., Fe hm , T.,
Marsc hner, N., Gluz , O., Schrade r, I., Hei nric h, G., Untch, M., & Jac ki sch, C.
(2013). HER2 Dime rizati on Inhi bi tor Pe rtuzuma b - Mode of Action and Cli nical
Data in Breast C ancer. B reast care (Basel , Swit ze rl and), 8 (1), 49–55.
Haya shi, N., Yama sa ki, A., Ueda , S., Okaz aki , S., Ohno, Y., Tana ka, T., E ndo, Y.,
Tom ioka, Y., Ma suko, K., Masuko, T., & Sugi ura , R. (2021). Onc oge nic
transforma tion of NIH/3T 3 cell s by t he overe xpre ssi on of L-t ype amino acid
transporte r 1, a promi sing a nti -ca ncer ta rget . Onc otarget, 12(13), 1256–1270.
Hill , A. G., Findla y, M. P., Burge , M. E ., Jac kson, C., Alfonso, P. G., Sa muel , L.,
Ganj u, V., Ka rtha us, M., Amatu, A., Je ffe ry, M., Ba rtolome o, M. D., B ridge water,
70
J., Covele r, A. L., Hidal go, M., Kapp, A. V., Sufan, R. I., Mc Call , B. B., Ha nle y,
W. D., Penuel, E. M., Pirzkall , A., … Ta bernero, J. (2018). Pha se II Study of t he
Dual E GFR/HER3 Inhibi tor Duligotuz umab (ME HD7945A) versus Cetuximab i n
Combinati on with FOL FIRI i n Sec ond -Line RAS Wil d- Type Meta stat ic Colorectal
Cancer. Cl inic al cance r rese arc h : an offici al journal of t he A me rican Associat ion
for Cance r Re search, 24 (10), 2276 –2284.
Hol bro, T., Beerli , R. R., Maurer, F., Kozicza k, M., Ba rba s, C. F., 3rd, & Hyne s,
N. E . (2003). T he ErbB2/ErbB3 het erodimer functions as an onc ogeni c unit: ErbB2
require s ErbB3 to dri ve brea st tum or cell prolife rati on. Proceedi ngs of the National
Acade my of Scie nce s of t he United States of A me rica, 100 (15), 8933–8938.
Hu, W. G. , Yi n, J., Cha u, D., Hu, C. C., Cherwonogrodzky, J. W. (20 14) . Anti body
Huma nizati on by a Single Cycle of CDR - Gra fting. Rici n Toxi n, 159- 181.
Hua ng, J., Wa ng, S., Lyu, H., Cai , B., Yang, X., Wang, J., & Li u, B. (2013). The
anti-e rbB3 ant ibody MM- 121/SAR256212 in com bination wit h tra st uzumab exert s
pote nt a ntit umor activi ty agai nst tra st uzuma b - re si stant brea st cancer cell s.
Molec ular canc er, 12 (1), 134.
Irie , H., Ka wa bata, R., Fujioka, Y., Nakagawa , F., Itada ni, H., Na ga se, H., It o, K.,
Uchi da,
J.,
Ohkubo,
S.,
Mat suo,
K.
(2020).
Acquired
resi sta nce
to
trastuz umab/ pert uzum ab or to T-DM1 in vivo ca n be ove rcome by HE R2 ki nase
inhi bition wit h TAS0728. Cance r science, 111 (6), 2123 –2131.
Ishimot o, T., Na gano, O., Yae , T., Tama da, M., Motohara , T., Os hima , H., Oshima,
M., Ikeda, T., Asa ba, R., Yagi, H., Ma suko, T., Shi mizu, T., Ishika wa, T., Kai, K.,
Takaha shi , E ., Imamura, Y., Baba , Y., Ohmura, M., Suem atsu, M., Baba , H., …
Saya , H. (2011). CD44 varia nt regulate s redox stat us i n c ance r ce ll s by stabil i zing
71
the xCT subuni t of system xc ( -) a nd the reby promote s tum or growth. Canc er cell ,
19(3), 387 –400.
Itoh, K., Inoue , K., Tez uka , T., Ta da, H., Ha shimot o, Y., Ma suko, T., & Suz uki , T.
(2003). Molecula r structural a nd functi onal cha racteriz ation of tumor suppre ssive
anti-E rbB- 2 monocl onal a nti body by pha ge display system. J ournal of bioc hemist ry,
133 (2), 239– 245.
Jeong, H., Kim, J., Lee, Y., Seo, J. H., Hong, S. R., & Kim, A. (2014). Neuregulin 1 i nduces ca ncer stem cell cha ra cteri stic s i n breast ca ncer cell li nes. Oncol ogy
report s, 32 (3), 1218 –1224.
Juric, D., Dienstma nn, R., Ce rvante s, A., Hidal go, M., Me ssersm i th, W.,
Blume nschei n, G. R., Jr, Ta bernero, J., Roda, D., Cal les, A., Jimeno, A., Wang, X.,
Bohórquez , S. S., Leddy, C., Litt man, C., Kapp, A. V., Shame s, D. S., Penuel, E.,
Amler,
L.
C.,
Pirz kall,
A.,
Pha rmac oki netic s/ Pha r macodynam ics
Ba selga,
of
t he
J.
(2015).
Fi rst -i n- Cla ss
Safe ty
Dual
and
Acti on
HER3/E GFR Ant ibody ME HD7945A i n L ocall y Adva nced or Meta sta tic Epitheli al
Tumors. Clinic al cancer rese arch : an off icial journal of t he A me ric an A ssoci ation
for Cance r Re search, 21 (11), 2462 –2470.
Kana i, Y., Se ga wa, H., Mi yamot o, K.i , Uc hino, H., Ta keda, E., & E ndou, H. (1998).
Expressi on cl oni ng a nd c haract eri zation of a t ransport er for la rge neutral am ino
acids acti vated by the hea vy c hain of 4F2 ant ige n (CD98). The Journal of
biol ogic al c he mi stry, 273 (37), 23629–23632.
Kanda samy, P., Gyi mesi, G., Kanai, Y., & Hedi ger, M. A. (2018). Ami no aci d
transporte rs re visited: Ne w views in healt h and di sea se . Trends i n bioc hemi cal
scie nces, 43 (10), 752 –789.
72
Kang, T. H., & Jung, S. T. (2019). Boosting t herape utic pote ncy of antibodie s by
taming Fc domai n functions. Expe ri ment al & molec ular medici ne, 51 (11), 1 –9.
Ka wakami , H., & Yone sa ka, K. (2016). HER3 and its Liga nd, He regul in, a s Target s
for Cance r The rapy. Rec ent pate nts on anti -c ance r drug discove ry, 11 (3), 267–274.
Kegye s, D., Const anti ne scu, C., Vrancken, L ., Ra sc he, L ., Gregoire , C., Tigu, B.,
Gule i, D., Dima , D., Tana se, A., E inse le, H., Ciurea, S., Tomulea sa , C., & Caers,
J. (2022). Patie nt selecti on for CAR T or BiTE the rap y in mul tiple myeloma: W hic h
treatment for eac h pa tient? . J ournal of hematol ogy & onc ol ogy, 15 (1), 78.
Kosc hut , D., Riche rt, L., Pace, G., Niemann, H. H., Mél y, Y., & Ori an -Roussea u,
V. (2016). Live cell ima ging shows hepat ocyte growt h factor - induced Me t
dimeriza tion. Bi ochimi ca et bi ophysic a acta , 1863(7 Pt A), 1552 –1558.
Kundranda, M., Gra cian, A. C., Zafar, S. F., Meiri , E., Bendell, J., Algül, H., Rive ra,
F., Ahn, E . R., Watkins, D., Pe lze r, U., Charu, V., Z alut skaya , A., Kue ste rs, G.,
Pipa s, J. M., Sa ntilla na, S., Askoxyla kis, V., & Ko, A. H. (2020). Randomize d,
double- bli nd, pla cebo -controlle d phase II study of i stirat umab (MM - 141) pl us na b paclita xel a nd gem citabi ne versus nab -pac litaxel a nd gemci tabi ne in front -li ne
metasta tic panc reatic canc er (CA RRIE ). Annal s of oncol ogy : offic ial j ournal of
the E urope an Society for Medic al Onc ology, 31 (1), 79 –87.
Labrij n, A. F., Janm aat, M. L., Reiche rt, J. M., & Pa rren, P. W. H. I. (2019).
Bispeci fic ant ibodie s: a me cha nist ic revie w of t he pi peli ne. Nat ure revi ews. Drug
disc ove ry, 18 (8), 585– 608.
Lehmann, F., & We nne rberg, J. ( 2021). Evolut ion of Nit rogen -Ba sed Alkylati ng
Anti cance r Age nt s. Processe s. 9(2), 377.
Lok, G. T., Cha n, D. W., Liu, V. W., Hui , W. W., Le ung, T. H., Yao, K. M., & Nga n,
73
H. Y. (2011). Aberrant acti vati on of ERK/ FOXM1 si gnali ng ca sca de tri gge rs t he
cell mi grati on/i nva si on in ovaria n cancer cell s. PloS one , 6(8), e23790.
Lu, R. M., Hwa ng, Y. C., Liu, I. J., Lee, C. C., Tsai , H. Z., Li, H. J., & Wu, H. C.
(2020). Development of t hera pe utic ant ibodie s for t he t reatme nt of disea se s.
Journal of biome dical scienc e, 27 (1), 1.
Lédel, F., Hall ström, M., Ra gnham mar, P., Öhrli ng, K., & E dler, D. (2014). HER3
expre ssi on in patient s with prima ry col orecta l ca ncer a nd corre sponding lym ph
node meta sta se s related to clini cal outc ome. European j ournal of c ancer (Oxf ord,
Engl and : 1990), 50 (3), 656 –662.
Lédel, F., Ste nstedt , K., Hall ström, M., Ra gnhammar, P., & Edle r, D . (2015). HE R3
expre ssi on i n prima ry col orectal cancer incl udi ng corre sponding metasta se s i n
lymph node and l iver. Act a onc ologica (Stock hol m, Swede n), 54 (4), 480 –486.
Maadi, H., Nami , B., Tong, J., Li, G., & Wang, Z. (2018). T he effect s of
trastuz umab on HE R2 -medi ated c ell si gna ling in CHO cell s e xpre ssing human
HER2. BMC c ancer, 18 (1), 238.
Mahl angu, J., Olde nburg, J., Paz - Priel, I., Ne grier, C., Niggli, M., Ma ncuso, M. E.,
Schm itt, C., Jimé nez -Yuste , V., Ke mpton, C., Dha llui n, C., Calla gha n, M. U., Buj a n,
W., Shima , M., Adam ke wicz, J. I., Asi kanius, E., Le vy, G. G., & Kruse - Jarres, R.
(2018). Emiciz uma b Prophyla xi s in Patie nt s Who Ha ve Hem ophi lia A wit hout
Inhi bit ors. The Ne w E ngl and journal of medi cine , 379 (9), 811– 822.
Ma suko T. (2021). Yak ugaku zasshi : Journal of the Pharmaceut ic al Society of
Japan, 141 (1), 81 –92.
Ma suko, K., Okazaki, S., Satoh, M., Ta naka , G., Ikeda , T., Tori i, R., Ue da, E.,
Naka no, T., Danbayashi, M., Tsuruoka , T., Ohno, Y., Yagi , H., Yabe , N., Yoshi da,
74
H., Tahara, T., Kata oka , S., Oshi no, T., Shindo, T., Ni wa, S., Ishimoto, T., …
Ma suko, T. (2012). Anti -tum or e ffect agai nst human ca ncer xenogra fts by a fully
huma n m onoclonal anti body to a variant 8 -epi tope of CD44R1 e xpre ssed on cance r
stem cell s. PloS one , 7(1), e29728.
Ma suko, T., Ohno, Y., Ma suko, K., Yagi , H., Uejima , S., Ta kechi , M., & Ha shimot o,
Y. (2011). Towards t herapeutic antibodie s to membrane onc oprotei ns by a robust
stra tegy using rat s immunized wit h tra nsfecta nt s expre ssing targe t m olecule s fuse d
to gree n fluore scent prote in. Canc er scie nce, 102 (1), 25 –35.
Mendell , J., Freema n, D. J., Feng, W., Hettm ann, T., Sc hnei der, M., Blum, S., Ruhe,
J., Bange, J., Nakama ru, K., Che n, S., Tsuchi ha shi , Z ., von Pa wel , J., Copigneaux,
C., & Bec kma n, R. A. (2015). Cli n ical Translati on a nd Valida tion of a Pre dicti ve
Bioma rke r for Pat ritum ab, a n Ant i -human Epi derm al Growth Factor Recept or 3
(HE R3) Monoclonal Anti body, i n Patients Wit h Adva nced Non - sm all Cell Lung
Cancer. EB ioMe dici ne, 2 (3), 264–271.
Milkereit , R., Pe rsau d, A., Va noaic a, L., Guet g, A., Ve rre y, F., & Roti n, D. (2015).
LAPT M4b re cruits t he LAT 1 - 4F2hc Le u t ransporte r to lysosomes and promot es
mTORC1 acti vation. Nature c ommunic ations, 6 , 7250.
Mi sale, S., Di Nic olant oni o, F., Sart ore -Bi anchi, A., Si ena , S., & Bardelli , A.
(2014). Re si stanc e t o anti -E GFR t herapy i n c olorectal cance r: from heteroge neity
to c onverge nt evoluti on. Canc er di scove ry, 4 (11), 1269–1280.
Mull ard A. (2017). Bi speci fic ant ibody pipeli ne move s beyond onc ology. Nature
revie ws. Drug di scovery, 16 (10), 666– 668.
NISONOFF, A., W ISSLER, F. C., & LIPMAN, L. N. (1960). Properti es of the maj or
compone nt of a peptic di ge st of ra bbi t a ntibody. Scie nce (Ne w York , N.Y.),
75
132 (3441), 1770–1771.
Naka mura , Y., Okamoto, W., Kato, T., E saki, T., Ka to, K., Komat su, Y., Yuki , S.,
Ma sui shi, T., Ni shina , T., Ebi, H., Sa wa da, K., Tani guc hi, H., Fuse , N., Nom ura,
S., Fukui, M., Mat suda , S., Saka moto, Y., Uc higat a, H., Kitaj ima, K., Kuram oto,
N., … Yoshino, T. (2021). Ci rculati ng t um or DNA -guide d treatment wit h
pert uzuma b plus t rastuz umab for HER2 -am pli fied meta static c ol ore ctal cance r: a
pha se 2 t rial . Nature me dici ne, 27 (11), 1899–1903.
Ogi , S., Fujita , H., Ka shi hara, M., Yama mot o, C., Sonoda, K., Okam oto, I. ,
Naka ga wa, K., Ohdo, S., Tana ka, Y., Kuwa no, M., & Ono, M. (2013). Sorting nexi n
2-me diated m embrane t rafficki ng of c - Met c ont ribute s to se nsitivi ty of molecula r targete d drugs. Cance r sci ence , 104 (5), 573–583.
Ogier, C., Col ombo, P. E ., Bousquet , C., Ca ntere l -Thoue nnon, L., Sica rd, P.,
Garam bois, V., Thoma s, G., Gaborit, N., Jarl ier, M., Pi rot , N., Pugni ère, M., Vi e,
N., Gongora, C., Ma rtine au, P., Robert , B., Pèl egrin, A., Chardès, T., & Larbouret,
C. (2018). Targeting t he NRG1/HE R3 pat hway in t umor cell s and c anc er -a ssociate d
fibrobl ast s wit h an a nti - neuregulin 1 anti body inhi bit s tum or growt h i n pre -cli nical
model s of pa ncrea tic ca ncer. Canc er l ette rs, 432 , 227–236.
Ohno, Y., Suda, K., Ma suko, K., Yagi , H., Ha shim oto, Y., & Ma suko, T. (2008).
Production and cha racte rizati on of highly t umor - speci fic ra t monocl onal antibodie s
recognizi ng the e xtrace llula r dom ain of human L -type a mino-aci d t ransporte r 1.
Canc er science , 99 (5), 1000 –1007.
Okaza ki, A., Shoji- Hosa ka, E ., Nakamura, K., Wakita ni , M., Uchida, K., Kakita,
S., Tsumot o, K., Kumagai , I., & Shitara , K. (2004). Fucose de pleti on from hum an
IgG1 oli gosacchari de enhanc es bi nding ent halpy a nd associati on rate between IgG1
76
and Fc gamma RIIIa. Journal of mol ecular biology, 336 (5), 1239–1249.
Okaza ki, S., Na katani, F., Ma suko, K., Tsuc hiha shi, K., Ueda , S., Ma suko, T., Saya ,
H., & Naga no, O. (2016). De vel opme nt of an ErbB4 m onoclonal antibody t hat
bloc ks neureguli n -1-induce d E rbB4 acti vati on i n cancer cel ls. Bi oche mical and
biophy sical research communicati ons, 470 (1), 239–244.
Okit a, K., Ha ra, Y., Okura, H., Hayashi, H., Sasa ki, Y., Ma suko, S., Kita dai, E .,
Ma suko, K., Yoshim oto, S., Ha ya shi, N., Sugi ura , R., Endo, Y., Oka zaki, S., Arai,
S., Yoshioka, T., Mat sumot o, T., Makino, Y., Komiyama, H., Sakamoto, K., &
Ma suko, T. (2021). Anti tum or effects of novel m Abs a gainst cat ionic ami no aci d
transporte r 1 (CAT 1) on hum an CRC wit h am plifi ed CAT1 ge ne. Cancer science ,
112(2), 563 –574.
Okit a, K., Okaza ki, S., U ej ima, S., Yam ada , E ., Kamina ka, H., Kondo, M., Ueda ,
S., Toki wa , R., Iwata , N., Yama saki, A., Ha ya shi , N., Ogura , D., Hirotani, K.,
Yoshioka, T., Inoue , M., Ma suko, K., & Masuko, T. (2020). Novel functional a nti HER3 monocl ona l anti bodie s wit h pot ent a nti -ca ncer effec ts on various huma n
epithel ial ca ncers. Onc otarget, 11(1), 31–45.
Palací n, M., Be rtra n, J., & Z orzano, A. (2000). He teromeric ami no aci d
transporte rs explain i nhe rite d ami noaci duria s. Curre nt opini on i n ne phrology and
hype rte nsi on, 9 (5), 547 –553.
Pang, Z., Dong, X., Deng, H., Wang, C., Lia o, X., L iao, C., Li ao, Y., Tian, W.,
Cheng, J., Chen, G., Yi , H., & Hua ng, L. (2022). MUC1 triggers li ne age plasticity
of He r2 posit ive mamma ry tum ors. Oncogene , 41 (22), 3064–3078.
Perez , S. M., Bri nton, L . T., & Kell y, K. A. (2021). Plecti n in Cance r: From
Bioma rke r t o T hera peutic Target. Cell s, 10 (9), 2246.
77
Pool, M., de Boer, H. R., Hooge, M. N. L., van Vugt , M. A. T. M., & de Vries, E .
G. E. (2017). Harne ssing Inte grati ve Omic s to Facili tate Molec ular Imaging of t he
Huma n Epide rmal Growt h Fact or Re cept or Famil y for Preci si on Medic ine .
The ranost ics, 7 (7), 2111 –2133.
Rexer, B. N., Ghosh, R., Na ra sanna, A., E st rada , M. V., Cha kra bart y, A., Song, Y.,
Engelma n, J. A., & Arteaga , C. L . (2013). Human brea st cance r cell s harbor ing a
gatekee per T798M m utation in HE R2 overe xpress E GFR li gands a nd are sensi tive
to dual inhibit ion of E GFR and HE R2. Cl inic al c ance r re se arc h : an official journal
of t he A me rican A ssociati on for Cance r Re se arc h, 19 (19), 5390 –5401.
Roopeni an, D. C., & Akile sh, S. (2007). Fc Rn: t he neonatal Fc rece ptor c ome s of
age. Nature revie ws. Immunology, 7 (9), 715–725.
Sait o, M., Kondo, M., Ohshima , M., Deguchi , K., Ha ya shi , H., Inoue, K., Tsuj i, D.,
Ma suko, T., & Itoh, K. (2014). Ide ntifica tion of anti -CD98 anti body mimotope s for
inducing ant ibodie s wit h antitum or act ivit y by mim otope im muniz ation. Cance r
scie nce, 105(4), 396–401.
Sampei,
Z .,
Iga wa,
T.,
Soe da,
T.,
Okuyama -Ni shida , Y.,
Moriyama,
C.,
Wakaba ya shi , T., Tana ka, E ., Mut o, A., Kojima , T., Kitaza wa , T., Yoshiha shi, K.,
Hara da, A., Funa ki, M., Ha raya , K., Tachi bana , T., Suz uki , S., E saki , K., Na buchi,
Y., & Ha ttori, K. (2013). Identi fi cation a nd mul tidime nsional opti mization of an
asym metric bi specifi c IgG a ntibody mimic king t he function of fact or VIII cofactor
activit y. PloS one , 8 (2), e57479.
Schnell , U., Ci rull i, V., & Giepma ns, B. N. (2013). EpCAM: structure and functi on
in health and di sea se. Bioc hi mica et bi ophysica act a, 1828 (8), 1989 –2001.
Schram, A. M., Odi ntsov, I., E spinosa -Cotton, M., Khodos, I., Si sso, W. J., Mattar,
78
M. S., L ui, A. J. W., Voj nic, M., Shameem, S. H., Chauhan, T., Torri si, J., Ford, J.,
O' Connor, M. N., Geuij e n, C. A. W., Schackma nn, R. C. J., Lamme rts va n Bue ren,
J. J., Wa sserm an, E., de Sta nchi na , E., O'Reil ly, E. M., La danyi, M., … Som war,
R. (2022). Ze noc utuz umab, a HER2xHE R3 Bi specific Anti body, Is E ffecti ve
Thera py for Tumors Drive n by NRG1 Gene Rearrang eme nts. Canc er disc ove ry,
12(5), 1233– 1247.
Sever, R., & Brugge , J. S. (2015). Signal tra nsduc tion in ca ncer. Cold Spri ng
Harbor perspec tive s in medici ne, 5(4), a 006098.
Sha o, Z., Pan, H., Tu, S., Zha ng, J., Yan, S., & Sha o, A. (2020). HGF/c - Met Axis:
The Advance d Deve lopment in Digestive System Cance r. F rontie rs i n cell and
development al biol ogy, 8 , 801.
Sjövall , A., Järv, V., Blom qvi st , L., Si ngnom klao, T., Ce derm ark, B., Glimeli us, B.,
& Holm , T. (2004). The potential for im prove d outc ome in patients with hepat ic
metasta se s from c olon cance r: a population - ba sed study. Europe an journal of
surgic al onc ology : the jour nal of the E urope an Socie ty of Surgical Onc ology and
the B riti sh A ssoci ation of Surgi cal Oncol ogy, 30 (8), 834 –841.
Slam on, D. J., Godolphin, W., Jones, L . A., Holt, J. A., Wong, S. G., Keith, D. E.,
Levin, W. J., St uart, S. G., Udove , J., & Ullric h, A. (1 989). Studie s of the HER 2/ne u prot o- onc oge ne i n human bre ast a nd ovaria n ca ncer. Scie nce (Ne w York , N.Y.),
244 (4905), 707 –712.
Soe rjom ataram , I., & Bra y, F. (2021). Planning for tom orrow: global ca ncer
incide nce and t he role of preve nti on 2020 - 2070. Nat ure revie ws. Cli ni cal onc ology,
18(10), 663– 672.
Sung, H., Ferlay, J., Sie gel, R. L ., Lave rsa nne , M., Soerj omata ram, I., Jemal, A.,
79
& Bra y, F. (2021). Global Canc er Stati stic s 2020: GLOBOCAN Estimat es of
Inci dence and Mortal ity Worldwi de for 36 Cance rs i n 1 85 Count rie s. CA : a c ance r
journal f or cli nici ans, 71 (3), 209 –249.
Tanizaki , J., Okamoto, I., Sakai , K., & Naka ga wa, K. (2011). Di ffe re ntial role s of
trans-phosphorylate d EGFR, HE R2, HE R3, and RET as hete rodimeri sa tion part ners
of MET i n lung ca ncer wit h MET amplifi cation. B rit ish journal of c ancer, 105 (6),
807 –813.
Toss, A., & Crist ofa nilli , M. (2015). Molecul ar c haracte rizati on and ta rgete d
thera peutic approache s in brea st c ancer. Bre ast c ance r re se arc h : B CR, 17 (1), 60.
Trenke r, R., Di wanji , D., & Jura , N. (2021). Muta nt HE R2 nee ds mutant HER3 t o
be a n effecti ve onc oge ne. Cell report s. Medici ne, 2 (8), 100361.
Turowec , J. P., Lau, E . W. T., Wa ng, X., Brown, K. R., Fel louse , F. A., Ja wanda, K.
K., Pa n, J., Moffat, J., & Si dhu, S. S. ( 2019). Func tional ge nomic c haracteri zation
of a synthetic anti - HER3 a ntibody reveal s a role for ubiquiti nation by RNF41 i n
the anti- prolife rative re sponse . The Journal of biol ogical che mi st ry, 294 (4), 1396 –
1409.
Tzahar, E., Wate rma n, H., Chen, X., Le vkowi tz, G., Ka runagaran, D., La vi, S.,
Ratzki n, B. J., & Ya rde n, Y. (1996). A hie rarc hical net work of inte rrece ptor
interact ions
det ermi ne s
signa l
tra nsduction
by
Ne u
differe ntiat ion
factor/ne ure guli n and epidermal growt h fact or. Mol ecul ar and cel lular biol ogy,
16(10), 5276 –5287
Ueda , S., Haya shi, H., Mi yamot o, T., Abe, S., Hi rai, K., Ma tsukura , K., Yagi , H.,
Hara , Y., Yoshi da, K., Okazaki, S., Tamura, M., Abe , Y., Agat suma , T., Ni wa , S. I.,
Ma suko, K., & Ma suko, T. (2019). Anti -tumor effect s of m Ab aga inst L -type ami no
80
acid tra nsporter 1 (LAT 1) bound to huma n and m onkey LAT 1 with dual avi dity
mode s. Cance r sc ience , 110 (2), 674–685.
Wang, S. C., Na kajima , Y ...
論文の公開元へ
